BIOABioAge Labs, Inc.
Price
+30%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Nothing alarming, growing in the filings, the market undecided.
We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging. In January 2025, we announced the nomination of our lead program, BGE-102, a potent, structurally novel, orally available, brain-penetrant small-molecule NLRP3 inhibitor.
In the company’s own words · 10-K filed Mar 24, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
BioAge Labs, Inc. (BIOA) reported revenue of $2.5M in Q2 2026 (quarter ended Jun 30, 2026), up 1.6% from the same quarter a year earlier. That came with net loss of $26M. For the full year FY2025, revenue was $9.0M and net income −$81M. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 2, 2026BioAge Labs, Inc. (the “Company”) recently announced that the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial evaluating once-daily oral BGE-102, an NLRP3 inhibitor, in adults with diabetic macular edema (“DME”), and provided updates on the QUELL-DME Phase 2 trial design.Other event · Form 8-K
- May 8, 2026BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates.Earnings release · press release
- Mar 24, 2026BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Drug Manufacturers, Specialty & Generic
The closest names by size in the same industry